The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: BioQuest

Interview With Garrett Herman Yields More Detail on the LOM-BioQuest Joint Venture

We have new details about the LOM-BioQuest joint venture that was announced last week.  The WSJ article about the JV emphasized the goals of supporting good science and expanding the two companies’ presence in the life sciences market.

I spoke to the Director of LOM BioQuest, Garrett Herman, and one of his associates yesterday about their vision for the joint venture.  They also shared with me the letter they sent announcing the JV (pdf).  Here are the highlights of the letter and our conversation:

  • They are taking a broad view of “life sciences” and plan to have the JV be the intake point for all their new projects in the space.
  • They want to take whatever approach will maximize the likelihood of good science succeeding and are willing to engage shareholders as well as management and boards.
  • Although the JV does not have any current employees, it does have “the full attention of both firms.”
  • For now, interested parties should contact the principals in the letter.
  • The plan is to nurture a few dramatic successes that will allow them to have an in-house source (or a regular stable) of capital to lead future deals, and a revived Canadian investor ecosystem to syndicate to.

I look forward to seeing LOM-BioQuest’s private sector approach to combining operating and financial advisory services, which should complement analogous efforts at NRC-IRAP and MaRS Innovation

Bookmark and Share

Monday Deal Review: August 17, 2009

B&W_BigNickelIn addition to the highlights already noted — Enobia’s $50 million r0und, and the LOM – BioQuest joint venture — there was plenty of other Canadian deal activity this week.  Check it out after the jump…

Q3 Is Looking Up for Biotech: Emdeon, Cumberland, Domain, LOM BioQuest, OETF

light at the end of the tunnel smallThis week has seen a continued upswing for biotech and other health industry companies in the U.S. (with two IPOs) and in Canada (with great VC news and the pending appointment of an administrator for the Ontario Emerging Technologies Fund):

In the U.S.

Here in Canada

In the pipeline

With personalized medicine seeing increasing validation as a clinical strategy, genomics technology will be key.  News this week from Helicos Biosciences that an individual’s complete genome was sequenced in one month for just $50k in consumables is an important marker (har) on the road to regular full-genome scans as part of our medical toolkit.

Share Button

Follow

Get every new post delivered to your Inbox.

Join 131 other followers